CollPlant Biotechnologies Ltd. (CLGN) Stock Score, Valuation & Financial Research
CollPlant Biotechnologies Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 20/100.
Quick answer for CLGN
CollPlant Biotechnologies Ltd. currently has a Wall Street Score of 20/100. The stored market price is $3.51. Its financial score is 8/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What CollPlant Biotechnologies Ltd. does
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its proprietary plant-based genetic engineering technology, which facilitates the production of recombinant type I human collagen. Its diverse product portfolio encompasses BioInks engineered for 3D tissue and organ fabrication; dermal and soft tissue fillers designed to diminish wrinkles; and innovative breast implants, both 3D bioprinted and injectable, aimed at promoting breast tissue regeneration. CollPlant also provides a 3D bioprinted regenerative soft tissue matrix. Specialized products include VergenixSTR, a soft tissue repair matrix targeting tendi
CLGN financial snapshot
- Wall Street Score:
- 20/100
- Current price:
- $3.51
- Market capitalization:
- $4.5M
- Revenue:
- $389K
- Net income:
- $-13.1M
- Free cash flow:
- $-9.4M
- Cash:
- $4.3M
- Total debt:
- $2.6M
- EPS:
- -10.30
- Financial score:
- 8/100
- Valuation score:
- 0/100
- Revenue score:
- 1/100
What stands out
- Reported year-over-year revenue growth is -0.8%.
- Free cash flow is $-9.4M, showing cash burn in the current stored period.
- The balance sheet shows $4.3M of cash versus $2.6M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 8/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-14.
How to research CLGN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.